Jade Biosciences Gets Two Catalysts, but Focus Is on 2027
Jade Biosciences began dosing patients in Phase 2 and first-in-human trials for kidney disease and rheumatoid arthritis. Shares traded at $21.50 premarket, down 21 cents. Interim data for both drugs are expected in 2027. Jade reported $311.3 million in cash as of March 31, enough to fund operations into 2028.
